1-3 of 3
Mariela Pantoja, PhD
Close
Sort by
Journal Articles

Myeloma Canada Research Network (MCRN)-001 ASCT Study of Busulfan + Melphalan (BuMel) Conditioning Followed By Lenalidomide (Len) Maintenance: Updated Results Including Serial Minimal Residual Disease (MRD) and Involved Serum Hevylite™ Chain (HLC) Ratio Assessments

Donna Reece, MD, Giovanni Piza Rodriguez, MD, Mariela Pantoja, PhD MSc, Darrell White, MD, Christopher P. Venner, MD, Julie Stakiw, MD, Michael Sebag, MD PhD, Terrance Comeau, MD, Kevin W. Song, MD, Jean Roy, MD, Martha L Louzada, MD, Arleigh McCurdy, MD, Vishal Kukreti, MD, Suzanne Trudel, MD, Anca Prica, MD, Rodger Tiedemann, MBChB, PhD, Christine Chen, MD, Harminder Paul, BSc
Journal: Blood
Blood (2016) 128 (22): 4632.
https://doi.org/10.1182/blood.V128.22.4632.4632
Published: 2016
Journal Articles

First Report of the Myeloma Canada Research Network (MCRN)-001 Trial Utilizing Bortezomib-Based Induction, Enhanced Conditioning with IV Busulfan + Melphalan (BuMel) and Lenalidomide Maintenance: Feasibility of a National Canadian Study Based on Achievement of Minimal Residual Disease (MRD) Negativity

Donna Reece, MD, Giovanni Piza Rodriguez, MD, Mariela Pantoja, PhD MSc, Christopher P. Venner, MD, Darrell White, MD, Julie Stakiw, MD, Michael Sebag, MD PhD, Terrance Comeau, MD, Kevin Song, MD, Jean Roy, MD, Leonard Minuk, MD, Jason Tay, MD MSc, Vishal Kukreti, MD, Suzanne Trudel, MD, Anca Prica, MD, Rodger Tiedemann, MBChB, PhD, Christine Chen, MD
Journal: Blood
Blood (2014) 124 (21): 3990.
https://doi.org/10.1182/blood.V124.21.3990.3990
Published: 2014
Journal Articles

A Phase I-II Trial of Bortezomib Plus Oral Cyclophosphamide and Prednisone for Relapsed/Refractory Multiple Myeloma.

Donna E. Reece, MD, Giovanni Piza, MD, Suzanne Trudel, MD, Mariela Pantoja, PhD, Christine Chen, MD, Joseph R. Mikhael, MD, Vishal Kukreti, MD, Keith Stewart, MD
Journal: Blood
Blood (2006) 108 (11): 3536.
https://doi.org/10.1182/blood.V108.11.3536.3536
Published: 2006